Related Experiment Video

Updated: Apr 16, 2026

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

14.3K

FFAR out new targets for diabetes

Kacey J Prentice1, Michael B Wheeler1

  • 1Department of Physiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.

Cell Metabolism
|March 5, 2015
PubMed

Insights

Dyslipidemia is linked to beta cell dysfunction in diabetes. New research shows that short-chain fatty acid receptors FFA2 and FFA3 in beta cells reduce insulin secretion in type 2 diabetes models.

Area of Science:

  • Endocrinology
  • Metabolic diseases
  • Molecular biology

Background:

  • Dyslipidemia is a known risk factor for beta cell dysfunction and the development of type 2 diabetes.
  • Beta cell dysfunction impairs insulin secretion, contributing to hyperglycemia.

Purpose of the Study:

  • To investigate the role of short-chain fatty acid receptors in beta cell function within type 2 diabetes models.
  • To elucidate the mechanism by which these receptors influence insulin secretion.

Main Methods:

  • Utilized type 2 diabetes models to examine beta cell function.
  • Investigated the activation and function of free fatty acid receptors 2 (FFA2) and 3 (FFA3) in beta cells.

Main Results:

  • FFA2 and FFA3 receptors are activated in an autocrine manner within beta cells.
  • Activation of these receptors leads to reduced insulin secretion in the context of type 2 diabetes.

Conclusions:

  • Short-chain fatty acid receptors FFA2 and FFA3 play a critical role in mediating beta cell dysfunction in type 2 diabetes.
  • Targeting these receptors may offer a novel therapeutic strategy for managing type 2 diabetes.

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.3K
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-1906:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.4K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
95
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.9K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.6K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.4K
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
651